Currently, few recommendations exist for patients with mild hemophilia, who represent approximately 60% of the hemophilia population. This study aims to provide objective data on joint health in these patients, which are currently limited compared to those with moderate or severe hemophilia.
The use of joint ultrasound in mild hemophilia could allow early, asymptomatic detection of joint damage, support tailored management including patient education, and ultimately improve quality of life.
The study will also explore the correlation between coagulation factor levels (FVIII or FIX) and other indicators of joint health in France.
Inclusion Criteria:
Exclusion Criteria:
Patient on prophylactic treatment, defined as at least one of the following:
o. ≥5 factor concentrate injections per month for a period of more than 6 months o. Treatment with emicizumab o. Last factor concentrate injection within the past 28 days
Patient with acquired hemophilia.
Patient with uncontrolled chronic rheumatologic disease, such as rheumatoid arthritis, inflammatory spondyloarthropathies, or microcrystalline arthritis.
Known pregnancy or breastfeeding.
Patient deprived of liberty or under legal guardianship or conservatorship.
laurent.frenzel@aphp.fr01 44 49 52 92 ext. +33
Patients with mild hemophilia will undergo an evaluation of joint health and functional status. Assessments will include joint ultrasound (HEAD-US) of six joints (ankles, knees, and elbows), blood sampling to determine FVIII or FIX activity, completion of functional, quality-of-life, and physical activity questionnaires, and clinical evaluation using the HemoFAST score. No therapeutic intervention or follow-up is planned as part of the study.
sarah.bouchard@aphp.fr01 42 19 28 79 ext. +33